Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
May 14, 2024
FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
➞
May 12, 2024
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
➞
May 08, 2024
Mabwell's MW032 Included in CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer
➞
May 06, 2024
FDA Grants Orphan Drug Designation to 9MW2821
➞
Apr 26, 2024
Mabwell to Debut Clinical Study Results of 9MW3011 at EHA2024
➞
Apr 25, 2024
Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor at ASCO 2024
➞
Apr 11, 2024
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
➞
Apr 03, 2024
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
➞
Mar 25, 2024
Mabwell ranks on the list of 2024 Top 100 Hardcore Technology Enterprises in Shanghai
➞
Mar 18, 2024
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London
➞
1
2
3
下一页